Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $212.8 million.

  • Contineum Therapeutics' Liabilities and Shareholders Equity fell 11.66% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $784.8 million, marking a year-over-year increase of 13.53%. This contributed to the annual value of $212.8 million for FY2024, which is 63.24% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Liabilities and Shareholders Equity of $212.8 million as of FY2024, which was up 63.24% from $130.4 million recorded in FY2023.
  • Contineum Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $212.8 million during FY2024, with a 5-year trough of $130.4 million in FY2023.
  • Its 2-year average for Liabilities and Shareholders Equity is $171.6 million, with a median of $171.6 million in 2023.
  • Data for Contineum Therapeutics' Liabilities and Shareholders Equity shows a peak YoY surged of 63.24% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $130.4 million in 2023, then skyrocketed by 63.24% to $212.8 million in 2024.